Microbiology Postanalytic Reporting

The scope of a reporting requirement depends on its source.

A preliminary or interim report communicates a verified finding before all planned work is complete. Examples include a direct smear, a positive blood-culture Gram stain, early colony growth, a provisional identification, or a rapid resistance marker. The status must be clear, and the report should identify pending work when that information affects interpretation. CMS defines a preliminary report by its timing before completion of the final result. Federal rules do not require a preliminary report at the first culture examination or for every specimen.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

A partial report contains completed components of a multi-test order while other components remain pending. A final report is issued when the testing planned for that order is complete. If an error is discovered later, issue a correction. If new information becomes available, use an addendum as defined by laboratory procedure.

Expected progression from preliminary identification to final identification and susceptibility is part of staged reporting when the earlier result was accurate and clearly incomplete. A correction is required when previously reported information was wrong. The system must preserve a retrievable chronology of what was released, its status, and its release time.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

When testing will exceed the laboratory's established reporting time, CLIA requires the laboratory to decide, according to the urgency of the test, whether the appropriate person must be notified. Use a downtime or alternate communication route when the delay could affect care.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

In microbiology, critical result is usually more accurate than critical value because many urgent findings are qualitative. Under CLIA, the laboratory must immediately alert the person or entity that requested the test and, when applicable, the person responsible for using the result when it indicates an imminently life-threatening condition or meets the laboratory's panic or alert criteria. To meet this federal requirement, the laboratory's approved policy specifies the results that trigger an alert, recipients, communication method, operational time limits, repeat rules, and escalation sequence.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

CLSI uses critical-risk result for a finding associated with an immediately life-threatening condition and significant-risk result for a finding that needs clinical review sooner than routine reporting. Laboratories may use terms such as urgent, priority, or significant, as defined in their written policy. CLSI recommends a process tailored to the patient population and care setting, with timely communication, verified receipt, escalation, documentation, and quality monitoring.^{44 Clinical and Laboratory Standards Institute. Management of Critical- and Significant-Risk Results. 2015.}

Microbiology findings that often need special handling include a positive direct stain or culture from blood or cerebrospinal fluid, organisms or parasites associated with rapidly progressive disease, a result that changes isolation precautions, a new resistance marker with an immediate treatment implication, and a presumptive organism that starts a public-health or referral pathway. The local policy assigns each finding to the appropriate clinical, infection-prevention, biosafety, or public-health route. The same result may follow more than one route.

Closed-loop communication

1. Verify the patient, specimen, result, report status, and any analytical limitation. Repeat testing follows the approved procedure. A routine repeat cannot replace CLIA's immediate alert when the released result already meets the alert criteria.
2. Send the result through the approved method to a recipient named in policy. Telephone, secure messaging, paging, and electronic alert systems may be used when they meet the applicable requirements and reliably confirm receipt.
3. Confirm that the recipient received and understood the result. Passive release to the health record completes a critical-result handoff only when the approved system supplies the required acknowledgement.
4. Document the date and time, patient and result, sender, recipient, communication method, confirmed receipt, and any required read-back.
5. If the first recipient cannot be reached, follow the timed escalation ladder, record each attempt, and continue until an authorized recipient accepts the result or the policy's final escalation point is reached.

CLIA contains no read-back instruction. The 2026 Joint Commission laboratory goal requires the organization to define who reports and receives critical results, set an acceptable reporting interval, document the process, and evaluate timeliness. Its elements of performance contain no read-back requirement.^{1,21 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.2 The Joint Commission. National Patient Safety Goals. 2025.} Some accreditors add one. The publicly available 2020 CAP Laboratory General Checklist requires requested and recorded read-back when a critical result is communicated verbally. Its electronic pathway requires confirmation of receipt. A CAP-accredited laboratory applies the current checklist edition and its own approved procedure.^{33 College of American Pathologists. Laboratory General Checklist. 2020.}

Monitor the interval from result availability to accepted notification, failed contacts, use of escalation, and communication errors. Read-back compliance is a useful measure when the procedure requires read-back.

An antimicrobial susceptibility testing (AST) report connects the organism and specimen with results produced by a validated method and interpreted with the applicable breakpoint source. The controlled procedure records the standard, edition, breakpoints, intrinsic-resistance rules, expert rules, and local drug-reporting policy in use. Those details are kept in procedure and validation records. CLIA does not require the CLSI edition to appear on every patient report.

The 2026 CLSI M100, 36th edition, supplies current bacterial drug-selection tiers, interpretation tables, quality-control criteria, and reporting comments, including its July 2026 correction.^{55 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 2026.} Method labeling and the laboratory's regulatory setting also affect which breakpoints apply.

Selective or cascade reporting releases a clinically appropriate subset of tested drugs according to the organism, specimen source, formulary, stewardship policy, and current standard. Suppressed results remain available through the laboratory's approved process when a clinician needs them. CDC describes selective reporting as a stewardship tool that requires coordination among microbiology, pharmacy, infectious diseases, and the antimicrobial stewardship program.^{66 Centers for Disease Control and Prevention. Selective Reporting of Antimicrobial Susceptibility Testing… 2020.} The testing methods, resistance mechanisms, M100 tiers, and antibiogram construction are covered in Antimicrobial Susceptibility Testing and Resistance Mechanisms.

A validated molecular assay may report a resistance marker before phenotypic AST is complete. The report identifies the target detected and any organism or specimen limitation. A negative panel supports absence only of the targets included in that panel. Later phenotypic results are an expected update when the earlier molecular report was accurate.

Whether a mechanism result changes a susceptible, intermediate, susceptible-dose dependent, or resistant category depends on the current breakpoints and expert rules. Detection of an extended-spectrum beta-lactamase or carbapenemase alone leaves some phenotypically susceptible categories unchanged under current breakpoints. Issue a correction when the earlier AST report was erroneous, such as use of the wrong breakpoint, patient association, transcription, organism identification, or validated expert rule.^{55 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 2026.}

Document critical-result communication, infection-prevention notification, public-health reporting, and final AST release individually, because completing one does not show that the others occurred.

Autoverification applies validated rules to release results without individual technical review. Results that fail a rule stop for review. Federal rules leave microbiology eligibility to the laboratory's validated system. The laboratory determines eligibility from the assay, result complexity, patient population, information systems, and required follow-up.

Rules should stop a result for review when assay controls, quality control, instrument status, interface transmission, specimen acceptability, or result checks fail. They must also account for critical-result communication, infection-prevention alerts, public-health reporting, reflex or confirmatory testing, and results that require individual interpretation. Autoverification never replaces a separate notification, referral, or documentation duty.

Before implementation, validate the complete path from the instrument or manual entry point to the final report destination. The challenge set includes results that should release and results that should stop for review. Assess every change to an assay, interface, rule, breakpoint, alert list, or reporting destination for revalidation. The record preserves the rule outcome, result, date and time, and identity of the person or system that released it. CLSI AUTO10 provides a general framework for design and validation. It is an archived guideline that CLSI retains as technically valid.^{77 Clinical and Laboratory Standards Institute. Autoverification of Clinical Laboratory Test Results. 2006.}

When an error is found in a reported patient result, CLIA requires the laboratory to promptly notify the authorized person who ordered the test and, when applicable, the person using the result. The laboratory must promptly issue a corrected report and retain the original and corrected reports. Notification begins when the reporting error is detected and does not wait for evidence that someone acted on the erroneous result.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

The immediate response is to contain and define the problem. Determine which patients, specimens, tests, instruments, reagent lots, interfaces, or reporting rules may be affected. Stop further release from the affected process when continued reporting could produce another error. Correct every affected report and use the critical-result escalation process when the change creates an immediate risk.

CMS interpretive guidance directs the corrected report to identify the corrected result and its corrected status clearly. Accreditation or local policy may also require the original and corrected information to appear together or remain electronically linked, with the reason and correction time visible to the recipient. The record preserves the notification and every report version.^{1,31 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.3 College of American Pathologists. Laboratory General Checklist. 2020.}

Microbiology corrections may follow a patient or specimen mismatch, transcription error, incorrect preliminary identification, mixed culture reported as a single organism, wrong breakpoint or expert rule, invalidated test run, or interface failure. Later completion of a correctly labeled preliminary workup remains part of staged reporting.

Every reporting error enters postanalytic quality assessment. The investigation identifies the scope and cause, corrects affected reports, addresses the process failure, and checks whether the action worked. The depth of investigation is proportional to patient risk and recurrence. Trend corrected reports, communication failures, delayed reports, and interface errors to find repeated system problems. CLIA requires ongoing assessment and corrective action. A formal root-cause analysis is reserved for errors whose risk or recurrence warrants that depth.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

Insufficient quantity is handled through the laboratory's specimen-acceptability and test-prioritization procedures. A limited specimen may support only part of an order. The report states the unacceptable condition and disposition when required. A corrected report is needed if a previously released result is later found invalid.

The patient report, internal testing record, and communication log serve different purposes.

A controlled correction preserves the original entry, corrected information, date and time, and person or system responsible for the change. On paper, a single-line strikeout with a dated initial is a common procedure because the original stays legible. Federal rules focus on attributable records and retention of original and corrected information, so the laboratory's controlled procedure defines the exact paper method. Electronic systems need a retrievable audit history that links the original and revised entries to the responsible person or system and the date and time.

CLIA generally requires at least 2 years of retention for test requisitions and authorizations; quality-control and patient test records; proficiency-testing records; quality-system-assessment records; and preliminary, final, and corrected reports. Pathology reports and specified pathology materials have longer federal periods. State law and accreditation requirements may extend the federal minimum.^{11 Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C. 2026.}

Release patient results only to an authorized person, an applicable person responsible for using the result, the referring laboratory, the patient or personal representative as allowed, or another recipient authorized by law. Verify the recipient and use the organization's secure communication process.

The Health Insurance Portability and Accountability Act (HIPAA) permits a covered laboratory to disclose protected health information to health care providers for treatment without patient authorization. The minimum-necessary rule does not apply to provider-to-provider treatment disclosures.^{88 US Department of Health and Human Services, et al. Uses and disclosures for treatment, payment, and health care…} HIPAA also permits disclosure to a public-health authority that is legally authorized to receive the information. Public-health disclosures generally follow the minimum-necessary standard. A disclosure required by law may include the information that law requires.^{99 US Department of Health and Human Services, et al. Disclosures for public health activities.}

The laboratory is responsible for an accurate and timely report, required immediate alerts, documented escalation to the designated recipient, corrections, retained records, assigned public-health reports and referrals, and consultation about test methods and limitations. The responsible clinical team interprets the result in the patient's full context and manages treatment and follow-up. Infection-prevention staff direct facility precautions and evaluate possible transmission. Public-health authorities classify cases, coordinate population-level investigation and control, and direct jurisdictional referral testing.

Joint Commission's May 2026 survey clarification focuses laboratory review on adherence to policy, documentation, and timely notification to the designated recipient. Hospital accreditation review traces the communication through to clinical action.^{1010 The Joint Commission. Survey updates for blood administration and critical result… 2026.}

The clinical microbiology laboratory supports infection prevention by promptly identifying and reporting epidemiologically important organisms and unusual resistance patterns through the facility's approved pathway. CDC guidance calls for systems that deliver these results to people who can act.^{1111 Centers for Disease Control and Prevention. CDC's core infection prevention and control practices for safe… 2024.} The facility defines its target list, recipients, urgency, and electronic or direct communication methods according to the patients it serves, current public-health guidance, and local transmission risks.

Targeted results commonly include organisms that change transmission-based precautions, multidrug-resistant organisms selected by the facility or health department, emerging pathogens, and laboratory patterns that may indicate health care transmission. The facility policy defines the operational list. For example, current CDC guidance specifically calls for prompt infection-prevention notification when Candida auris is suspected and immediate reporting of confirmed results through the applicable public-health process.^{1212 Centers for Disease Control and Prevention. Laboratory information for Candida auris. 2026.}

Escalate an unusual cluster, repeated rare organism, or unexpected resistance pattern to a supervisor and infection prevention according to policy. Infection prevention and the health care epidemiology team determine whether the pattern represents transmission or an outbreak and coordinate the response. When a patient moves to another facility, the sending care organization communicates required precautions and targeted multidrug-resistant organism status. The laboratory supplies accurate reports and any result clarification needed for that handoff.^{1111 Centers for Disease Control and Prevention. CDC's core infection prevention and control practices for safe… 2024.}

Antibiograms and resistance summaries support infection prevention and antimicrobial stewardship. Submission to CDC's National Healthcare Safety Network (NHSN) depends on the facility type, reporting program, measure, and applicable federal or state requirement. Participation in one NHSN measure creates the duties defined by that measure.

State, territorial, and local laws create the duty to report communicable diseases and laboratory findings. The jurisdiction determines whether the laboratory, clinician, facility, or more than one reporter has a duty. It also sets the deadline, data elements, communication route, and specimen or isolate submission requirement. One reporter's action satisfies another reporter's duty only when the jurisdiction's rule says so.

National notification is a separate surveillance step. The Council of State and Territorial Epidemiologists recommends nationally notifiable conditions in collaboration with CDC, and CDC administers the National Notifiable Diseases Surveillance System (NNDSS). Jurisdictions collect identified reports under their own laws and voluntarily send case notifications to CDC. A nationally notifiable condition may have different reporting requirements across jurisdictions, and a state may require conditions beyond the national list.^{1313 Centers for Disease Control and Prevention. Readers' Guide. 2024.}

CDC updates the national list and surveillance definitions each year. Its April 2026 notice for the 2026 weekly tables added COVID-19-associated pediatric mortality, placed non-congenital Oropouche in weekly and annual tables and congenital Oropouche in annual tables, and removed dengue-like illness. Dengue and severe dengue were retained. The current jurisdictional rule sets the clinical laboratory's reporting route and deadline.^{1414 Centers for Disease Control and Prevention. Notice to data users and publication criteria. 2026.}

Electronic laboratory reporting can transmit routine results to a health department, but its legal effect depends on the jurisdiction. If state or local law also requires immediate direct notification for a specific result, the laboratory completes that contact and documents it. Maintain a current jurisdiction-specific list and workflow, because a static national disease list does not include each jurisdiction's requirements.

Some public-health rules require an original specimen, isolate, or other material for confirmation, typing, or surveillance. Contact the designated public-health laboratory before shipment, follow its acceptance and packaging instructions, and document the transfer. Referral of the material and submission of the case report are separate steps unless the jurisdiction combines them.

For organisms within the Laboratory Response Network (LRN) sentinel scope, follow the current organism-specific American Society for Microbiology (ASM) and Association of Public Health Laboratories (APHL) protocol, contact the designated LRN reference laboratory before transfer, and make the public-health notifications required by state and local law.^{1515 American Society for Microbiology. Laboratory Response Network sentinel level clinical laboratory…} Once a select agent or toxin is identified, Federal Select Agent Program rules set the federal reporting, security, and final disposition requirements for a laboratory using the diagnostic-specimen exemption.^{1616 Federal Select Agent Program. Information for clinical and diagnostic laboratories, healthcare…}

The current federal select-agent list and the current sentinel protocol serve different purposes. Brucella abortus, B. melitensis, and B. suis were removed from the federal select-agent list on January 16, 2025. ASM's updated sentinel guidance continues a public-health consultation and referral pathway for suspected brucellosis-causing Brucella species.^{17,1517 Federal Select Agent Program. Reminder: changes to select agent and toxin list are effective… 2025.15 American Society for Microbiology. Laboratory Response Network sentinel level clinical laboratory…}

The laboratory reports and refers the finding, preserves confidentiality, and supplies technical information. Decisions about patient treatment, isolation orders, contact prophylaxis, public notification, outbreak declaration, and law-enforcement involvement are made by the responsible clinical, infection-prevention, public-health, and governmental authorities. At the bench, before you finalize a report, confirm that each required communication, from the care team to public health, is documented separately.